Pelthos Therapeutics Inc. (PTHS) insider buying and selling

NYSE: PTHS · Source: SEC Form 4 filings · Latest trade reported

There were no open-market insider purchases or sales at Pelthos Therapeutics Inc. (PTHS) in the last 90 days. Over the last 12 months, 1 insider bought $1000K of the stock, led by Todd C Davis (Director), who bought $1000K on Jun 11, 2026; 4 insiders sold $104K, of which $64K was scheduled or tax-related.

Insider buys, 90 days
0
$0 · 0 insiders
Insider sales, 90 days
0
$0 · 0 insiders
Insider buys, 12 months
2
$1000K · 1 insider
Insider sales, 12 months
9
$104K · 4 insiders

This is the public summary. Create a free account to see PTHS’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.

Unlock PTHS

Recent open-market insider trades

Trades by the same insider within a week are shown as one line.

Open-market insider trades at Pelthos Therapeutics Inc.
DateInsiderTypeSharesPriceValue
Todd C Davis
Director
Open market purchase
2 trades
35,948avg. $27.82$1000K
Knuettel Francis II
CFO
Open market sale1,500$26.84$40K

Scheduled and tax-related sales

Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.

Scheduled and tax-related insider sales at Pelthos Therapeutics Inc.
DateInsiderTypeSharesPriceValue
Peter Greenleaf
Director
10b5-1 sale
2 trades
797avg. $26.13$21K
Matthew Pauls
Director
10b5-1 sale
2 trades
786avg. $26.16$21K
Ezra M Friedberg
Director
10b5-1 sale
2 trades
558avg. $26.09$15K
Ezra M Friedberg
Director
10b5-1 sale
2 trades
283avg. $27.29$8K

What the PTHS insider trades really mean

The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Pelthos Therapeutics Inc. and every other stock we track:

The AI Signal weighs:Insider buyingAnalyst ratingPrice upsideAI OutlookInsider track recordBreakout pressure

Plus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.

Get started free with PTHS Insider Intel tracks insider activity at 3,154 companies right now. The Free plan includes full price charts and trade history, watchlists and email alerts.

Questions about PTHS insider trading

Who bought Pelthos Therapeutics Inc. (PTHS) stock recently?

Insiders who bought Pelthos Therapeutics Inc. stock on the open market in the last 12 months: Todd C Davis ($1000K). The most recent purchase was reported on Jun 11, 2026.

Are insiders buying or selling PTHS?

Over the last 12 months insiders were net buyers of PTHS on discretionary trades: $1000K bought against $40K sold (scheduled and tax-related sales excluded).

What is a sell-to-cover or 10b5-1 sale?

A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.

Where does this data come from?

Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.

Other stocks with recent insider buying

Ready to see PTHS in full?

Create a free account and open its chart, score and alerts.

Create your free account

How to read this page

Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.

Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.